Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15342270 | 1.00 | SLC6A4 (0.55) | SLC6A4TAAR1 | |
| Hydrochloric Acid SCHEMBL11209663 | 0.98 | SLC6A4 (0.53) | SLC6A4TAAR1 | |
| SCHEMBL20386033 | 0.86 | ALOX15 (0.50) | — | |
| SCHEMBL2559132 | 0.86 | SLC6A4 (0.55) | SLC6A4TAAR1 | |
| SCHEMBL30797834 | 0.86 | SLC6A4 (0.55) | SLC6A4TAAR1 | |
| SCHEMBL31545634 | 0.85 | LDHA (0.59) | SLC6A4TAAR1 | |
| SCHEMBL2564908 | 0.85 | LDHA (0.59) | SLC6A4TAAR1 | |
| SCHEMBL31545527 | 0.85 | LDHA (0.59) | SLC6A4TAAR1 | |
| SCHEMBL3371646 | 0.85 | LDHA (0.59) | SLC6A4TAAR1 | |
| SCHEMBL266195 | 0.85 | LDHA (0.59) | SLC6A4TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-0255728-B1 | PHENOXYACETIC ACID COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE | TANABE SEIYAKU CO., LTD. (JP) | 1991-11-27 | — | — | EP | disclosed |
| US-4866196-A | ANTICOAGULANTS | TANABE SEIYAKU CO., LTD. (JP) | 1989-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP30, USP8 | SLC6A4 3510/4885TAAR1 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.